Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

J.D. Doecke; L. Ward; S.C. Burnham; V.L. Villemagne; Q-X Li; S. Collins; C.J. Fowler; E. Manuilova; M. Widmann; S.R. Rainey-Smith; R.N. Martins; C.L. Masters

doi:10.1186/s13195-020-00595-5

Back

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

Journal article

Open access

Peer reviewed

Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging

J.D. Doecke, L. Ward, S.C. Burnham, V.L. Villemagne, Q-X Li, S. Collins, C.J. Fowler, E. Manuilova, M. Widmann, S.R. Rainey-Smith, …

Alzheimer's Research & Therapy, Vol.12(1), Art. 36

2020

DOI: https://doi.org/10.1186/s13195-020-00595-5

Files and links (2)

pdf

BiomarkerImmunoassay.pdfDownload View

Published (Version of Record) Open Access

url

Free to Read *No subscription requiredView

Abstract

Background β-amyloid (Aβ) positron emission tomography (PET) imaging is currently the only Food and Drug Administration-approved method to support clinical diagnosis of Alzheimer’s disease (AD). However, numerous research studies support the use of cerebrospinal fluid (CSF) biomarkers, as a cost-efficient, quick and equally valid method to define AD pathology. Methods Using automated Elecsys® assays (Roche Diagnostics) for Aβ (1–42) (Aβ42), Aβ (1–40) (Aβ40), total tau (tTau) and phosphorylated tau (181P) (pTau), we examined CSF samples from 202 participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing cohort, to demonstrate the concordance with pathological AD via PET imaging. Results Ratios Aβ42/Aβ40, tTau/Aβ42 and pTau/Aβ42 had higher receiver operator characteristic—area under the curve (all 0.94), and greater concordance with Aβ-PET (overall percentage agreement ~ 90%), compared with individual biomarkers. Conclusion Strong concordance between CSF biomarkers and Aβ-PET status was observed overall, including for cognitively normal participants, further strengthening the association between these markers of AD neuropathological burden for both developmental research studies and for use in clinical trials.

Details

Title: Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging
Authors/Creators: J.D. Doecke (Author/Creator) - Australian e-Health Research Centre
L. Ward (Author/Creator) - Cooperative Research Centre for Mental Health
S.C. Burnham (Author/Creator) - Australian e-Health Research Centre
V.L. Villemagne (Author/Creator) - Florey Institute of Neuroscience and Mental Health
Q-X Li (Author/Creator) - Florey Institute of Neuroscience and Mental Health
S. Collins (Author/Creator) - The University of Melbourne
C.J. Fowler (Author/Creator) - Florey Institute of Neuroscience and Mental Health
E. Manuilova (Author/Creator) - Roche Applied Science
M. Widmann (Author/Creator) - Roche Diagnostics GmbH, Mannheim, Germany
S.R. Rainey-Smith (Author/Creator)
R.N. Martins (Author/Creator) - Macquarie University
C.L. Masters (Author/Creator) - Florey Institute of Neuroscience and Mental Health
Publication Details: Alzheimer's Research & Therapy, Vol.12(1), Art. 36
Publisher: Biomed Central
Identifiers: 991005541978407891
Copyright: © 2020 The Authors.
Murdoch Affiliation: Murdoch University
Language: English
Resource Type: Journal article

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Metrics

23 File views/ downloads

69 Record Views

66 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.52 Neurodegenerative Diseases; 1.52.60 Dementia
Web Of Science research areas: Clinical Neurology; Neurosciences
ESI research areas: Neuroscience & Behavior